195 related articles for article (PubMed ID: 29793878)
1. TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.
Xiao W; Du N; Huang T; Guo J; Mo X; Yuan T; Chen Y; Ye T; Xu C; Wang W; Wang G; Cai S; Chen J
EBioMedicine; 2018 Jun; 32():119-124. PubMed ID: 29793878
[TBL] [Abstract][Full Text] [Related]
2. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
DeLeon TT; Almquist DR; Kipp BR; Langlais BT; Mangold A; Winters JL; Kosiorek HE; Joseph RW; Dronca RS; Block MS; McWilliams RR; Kottschade LA; Rumilla KM; Voss JS; Seetharam M; Sekulic A; Markovic SN; Bryce AH
PLoS One; 2020; 15(3):e0230306. PubMed ID: 32196516
[TBL] [Abstract][Full Text] [Related]
3. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
4. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
[TBL] [Abstract][Full Text] [Related]
5. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
Front Immunol; 2020; 11():590618. PubMed ID: 33391264
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
7. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
[TBL] [Abstract][Full Text] [Related]
8. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
9. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients.
Jensen C; Madsen DH; Hansen M; Schmidt H; Svane IM; Karsdal MA; Willumsen N
J Immunother Cancer; 2018 Dec; 6(1):152. PubMed ID: 30567561
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
12. The Predictive Value of
Ye T; Zhang JY; Liu XY; Zhou YH; Yuan SY; Yang MM; Xie WZ; Gao C; Chen YX; Huang ML; Ye CZ; Chen J
Front Immunol; 2021; 12():785526. PubMed ID: 35069558
[TBL] [Abstract][Full Text] [Related]
13. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
14. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
15. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
[TBL] [Abstract][Full Text] [Related]
16. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
[TBL] [Abstract][Full Text] [Related]
17. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
19. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
[No Abstract] [Full Text] [Related]
20. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
